128 related articles for article (PubMed ID: 27076624)
1. A Promyelocytic Leukemia Protein-Thrombospondin-2 Axis and the Risk of Relapse in Neuroblastoma.
Dvorkina M; Nieddu V; Chakelam S; Pezzolo A; Cantilena S; Leite AP; Chayka O; Regad T; Pistorio A; Sementa AR; Virasami A; Barton J; Montano X; Lechertier T; Brindle N; Morgenstern D; Lebras M; Burns AJ; Saunders NJ; Hodivala-Dilke K; Bagella L; De The H; Anderson J; Sebire N; Pistoia V; Sala A; Salomoni P
Clin Cancer Res; 2016 Jul; 22(13):3398-409. PubMed ID: 27076624
[TBL] [Abstract][Full Text] [Related]
2. Promyelocytic leukemia-nuclear body formation is an early event leading to retinoic acid-induced differentiation of neuroblastoma cells.
Delaune A; Corbière C; Benjelloun FD; Legrand E; Vannier JP; Ripoll C; Vasse M
J Neurochem; 2008 Jan; 104(1):89-99. PubMed ID: 17986232
[TBL] [Abstract][Full Text] [Related]
3. Expression of a MYCN-interacting isoform of the tumor suppressor BIN1 is reduced in neuroblastomas with unfavorable biological features.
Tajiri T; Liu X; Thompson PM; Tanaka S; Suita S; Zhao H; Maris JM; Prendergast GC; Hogarty MD
Clin Cancer Res; 2003 Aug; 9(9):3345-55. PubMed ID: 12960121
[TBL] [Abstract][Full Text] [Related]
4. A novel amplification gene PCI domain containing 2 (PCID2) promotes colorectal cancer through directly degrading a tumor suppressor promyelocytic leukemia (PML).
Zhang J; Zhai J; Wong CC; Chen H; Wang X; Ji J; Yu J
Oncogene; 2021 Dec; 40(49):6641-6652. PubMed ID: 34625711
[TBL] [Abstract][Full Text] [Related]
5. Restoration of promyelocytic leukemia protein-nuclear bodies in neuroblastoma cells enhances retinoic acid responsiveness.
Yu JH; Nakajima A; Nakajima H; Diller LR; Bloch KD; Bloch DB
Cancer Res; 2004 Feb; 64(3):928-33. PubMed ID: 14871822
[TBL] [Abstract][Full Text] [Related]
6. Clinically Relevant Cytotoxic Immune Cell Signatures and Clonal Expansion of T-Cell Receptors in High-Risk
Wei JS; Kuznetsov IB; Zhang S; Song YK; Asgharzadeh S; Sindiri S; Wen X; Patidar R; Najaraj S; Walton A; Auvil JMG; Gerhard DS; Yuksel A; Catchpoole D; Hewitt SM; Sondel PM; Seeger R; Maris JM; Khan J
Clin Cancer Res; 2018 Nov; 24(22):5673-5684. PubMed ID: 29784674
[No Abstract] [Full Text] [Related]
7. The PML gene is not involved in the regulation of MHC class I expression in human cell lines.
Bruno S; Ghiotto F; Fais F; Fagioli M; Luzi L; Pelicci PG; Grossi CE; Ciccone E
Blood; 2003 May; 101(9):3514-9. PubMed ID: 12506025
[TBL] [Abstract][Full Text] [Related]
8. Network Modeling of microRNA-mRNA Interactions in Neuroblastoma Tumorigenesis Identifies miR-204 as a Direct Inhibitor of MYCN.
Ooi CY; Carter DR; Liu B; Mayoh C; Beckers A; Lalwani A; Nagy Z; De Brouwer S; Decaesteker B; Hung TT; Norris MD; Haber M; Liu T; De Preter K; Speleman F; Cheung BB; Marshall GM
Cancer Res; 2018 Jun; 78(12):3122-3134. PubMed ID: 29610116
[TBL] [Abstract][Full Text] [Related]
9. GRHL1 acts as tumor suppressor in neuroblastoma and is negatively regulated by MYCN and HDAC3.
Fabian J; Lodrini M; Oehme I; Schier MC; Thole TM; Hielscher T; Kopp-Schneider A; Opitz L; Capper D; von Deimling A; Wiegand I; Milde T; Mahlknecht U; Westermann F; Popanda O; Roels F; Hero B; Berthold F; Fischer M; Kulozik AE; Witt O; Deubzer HE
Cancer Res; 2014 May; 74(9):2604-16. PubMed ID: 24419085
[TBL] [Abstract][Full Text] [Related]
10. Importance of ERK activation in As2O3-induced differentiation and promyelocytic leukemia nuclear bodies formation in neuroblastoma cells.
Petit A; Delaune A; Falluel-Morel A; Goullé JP; Vannier JP; Dubus I; Vasse M
Pharmacol Res; 2013 Nov; 77():11-21. PubMed ID: 24004656
[TBL] [Abstract][Full Text] [Related]
11. Expression of promyelocytic leukemia protein increases during the differentiation of human neuroblastoma cells.
Yu E; Choi EK; Kim CJ
Virchows Arch; 2003 Mar; 442(3):278-83. PubMed ID: 12647219
[TBL] [Abstract][Full Text] [Related]
12. MYCN and ALKF1174L are sufficient to drive neuroblastoma development from neural crest progenitor cells.
Schulte JH; Lindner S; Bohrer A; Maurer J; De Preter K; Lefever S; Heukamp L; Schulte S; Molenaar J; Versteeg R; Thor T; Künkele A; Vandesompele J; Speleman F; Schorle H; Eggert A; Schramm A
Oncogene; 2013 Feb; 32(8):1059-65. PubMed ID: 22484425
[TBL] [Abstract][Full Text] [Related]
13. Concordant expression of proto-oncogene promyelocytic leukemia and major histocompatibility antigen HLA class I in human hepatocellular carcinoma.
Xia M; Zhang JQ; Shen YQ; Xu LH; Chen AQ; Miao FQ; Xie W
Tissue Antigens; 2007 Oct; 70(4):272-82. PubMed ID: 17767548
[TBL] [Abstract][Full Text] [Related]
14. Proliferation and Survival of Embryonic Sympathetic Neuroblasts by MYCN and Activated ALK Signaling.
Kramer M; Ribeiro D; Arsenian-Henriksson M; Deller T; Rohrer H
J Neurosci; 2016 Oct; 36(40):10425-10439. PubMed ID: 27707976
[TBL] [Abstract][Full Text] [Related]
15. In vivo angiogenic activity of neuroblastoma correlates with MYCN oncogene overexpression.
Ribatti D; Raffaghello L; Pastorino F; Nico B; Brignole C; Vacca A; Ponzoni M
Int J Cancer; 2002 Dec; 102(4):351-4. PubMed ID: 12402304
[TBL] [Abstract][Full Text] [Related]
16. Activated Alk triggers prolonged neurogenesis and Ret upregulation providing a therapeutic target in ALK-mutated neuroblastoma.
Cazes A; Lopez-Delisle L; Tsarovina K; Pierre-Eugène C; De Preter K; Peuchmaur M; Nicolas A; Provost C; Louis-Brennetot C; Daveau R; Kumps C; Cascone I; Schleiermacher G; Prignon A; Speleman F; Rohrer H; Delattre O; Janoueix-Lerosey I
Oncotarget; 2014 May; 5(9):2688-702. PubMed ID: 24811913
[TBL] [Abstract][Full Text] [Related]
17. Biological effects of induced MYCN hyper-expression in MYCN-amplified neuroblastomas.
Torres J; Regan PL; Edo R; Leonhardt P; Jeng EI; Rappaport EF; Ikegaki N; Tang XX
Int J Oncol; 2010 Oct; 37(4):983-91. PubMed ID: 20811720
[TBL] [Abstract][Full Text] [Related]
18. Loss of the tumor suppressor PML in human cancers of multiple histologic origins.
Gurrieri C; Capodieci P; Bernardi R; Scaglioni PP; Nafa K; Rush LJ; Verbel DA; Cordon-Cardo C; Pandolfi PP
J Natl Cancer Inst; 2004 Feb; 96(4):269-79. PubMed ID: 14970276
[TBL] [Abstract][Full Text] [Related]
19. S(+)-ibuprofen destabilizes MYC/MYCN and AKT, increases p53 expression, and induces unfolded protein response and favorable phenotype in neuroblastoma cell lines.
Ikegaki N; Hicks SL; Regan PL; Jacobs J; Jumbo AS; Leonhardt P; Rappaport EF; Tang XX
Int J Oncol; 2014 Jan; 44(1):35-43. PubMed ID: 24173829
[TBL] [Abstract][Full Text] [Related]
20. Dual regulation of Stat1 and Stat3 by the tumor suppressor protein PML contributes to interferon α-mediated inhibition of angiogenesis.
Hsu KS; Zhao X; Cheng X; Guan D; Mahabeleshwar GH; Liu Y; Borden E; Jain MK; Kao HY
J Biol Chem; 2017 Jun; 292(24):10048-10060. PubMed ID: 28432122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
